Nektar Therapeutics DEF 14A proxy statements

Nektar Therapeutics has issued its 2026 proxy statement, seeking shareholder approval for director election, an increase in equity plan shares, and executive compensation.

Nektar Therapeutics is asking stockholders to vote on several proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and amendments to its incentive plan.

Nektar Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Nektar Therapeutics is holding its annual stockholder meeting on June 5, 2024, to vote on director elections, an amendment to the performance incentive plan, ratification of the accounting firm, and executive compensation.